AbbVie Submits Rinvoq Regulatory Applications to FDA, EMA
June 01 2020 - 12:31PM
Dow Jones News
By Stephen Nakrosis
AbbVie Inc. on Monday said it was submitting applications to the
U.S. Food and Drug Administration and the European Medicines Agency
for its Rinvoq to treat patients with active psoriatic
arthritis.
Psoriatic arthritis is an inflammatory condition that affects
people suffering from psoriasis.
The company said it based its submissions on "two Phase 3
studies in which Rinvoq demonstrated improved joint outcomes,
physical function and skin symptoms, with a greater proportion of
patients achieving minimal disease activity versus placebo."
The company said Rinvoq, or upadacitinib, was "discovered and
developed by AbbVie scientists" and is a "selective and reversible
JAK inhibitor that is being studied in several immune-mediated
inflammatory diseases."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 01, 2020 12:16 ET (16:16 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.